SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates significant announcements and potential partnerships at an upcoming crypto conference in Las Vegas. Holders are discussing the project's long-term utility and compliance, focusing on accumulation strategies while navigating current market volatility.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as a highly speculative asset with community members highlighting ongoing token burns and potential new ecosystem projects as catalysts for a long-term reversal. While some investors remain hopeful for a significant recovery, others remain highly skeptical due to the project's historical volatility and the persistence of diverse, contrasting community sentiment regarding its future.

Julong Holding Ltd. engages in the business of investment holding activities. It provides intelligent integrated solutions to public utilities, enterprises, commercial, and multifamily properties. The company was founded by Jia Qi Hu on August 07, 2023 and is headquartered in Beijing, China.

Julong Holding Ltd. - Ordinary Shares - Class A

Julong Holding Ltd. is experiencing high volatility as retail traders push for a short squeeze, drawn by its extremely low float and high insider ownership. The community is actively tracking the stock's frequent trading halts and comparing its potential for parabolic gains to other recent low-float China-based market runners.

"What's Updog?" is a Community Led token.

UpDog

UpDog is seeing a surge in community-driven engagement and whale accumulation on the Solana blockchain as investors rally behind its long-standing meme-focused ecosystem. While proponents highlight its consistent organic growth and locked liquidity, the project continues to spark intense debate among traders regarding its long-term viability as a speculative asset.

Dumb SEND IT

The $DSIT community is rallying behind a 'dumb send it' strategy, with the developer actively engaging followers and promoting airdrop incentives to push the token toward a higher market cap. Investors are discussing the project's recent growth, community-driven marketing efforts, and the belief that the current entry point represents an opportunity before potential broader momentum.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing significant community attention as investors debate its long-term potential and consolidation patterns. Enthusiasts are actively sharing bullish outlooks and comparing the asset to other meme coins, while some traders express frustration over current price stagnation and recent market volatility.

ETHGas is a Blockspace Infrastructure protocol that decomposes Ethereum blockspace into tradable, composable block units, enabling real‑time block production and laying the foundation for a crypto‑native commodities market for gas. By restructuring gas as a financial primitive, ETHGas unlocks: - Faster block times (sub‑second confirmations vs 12‑second Ethereum blocks) through real‑time sequencing. - A futures/forward market for gas, enabling the creation of a native Ethereum yield curve. - Gas abstraction for end users via the Open Gas Initiative, removing gas volatility and shifting costs to protocols. - Commoditization of blockspace, similar to energy or metals markets in traditional finance.

ETHGas

GWEI is trending as investors focus on its utility in streamlining Ethereum transactions and reducing gas fee volatility through blockspace futures. The community is highlighting the project's recent exchange listings, institutional partnerships, and its potential to benefit from broader positive shifts in the crypto regulatory and market environment.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating buzz across social media as investors cross-reference the ticker with other emerging crypto assets to gauge potential market momentum and community sentiment.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense community debate over its long-term utility versus its stagnant price action, as investors closely monitor pending legislative developments and potential institutional integration news. Discussions are heavily divided between frustrated holders questioning the timeline for meaningful gains and optimistic bulls pointing to ongoing institutional partnerships and infrastructure developments.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy Corp. (VLO) is trending due to heightened volatility in energy markets triggered by Middle East geopolitical tensions, which have significantly widened refining crack spreads and boosted short-term profit expectations. The community is actively discussing the stock's role as a play on shifting global supply chains and its ability to maintain operational resilience despite a challenging refining margin environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2-Q3, PTSD Plan for 2027

Definium Therapeutics (NASDAQ:DFTX) used a company event to outline its late-stage development plans for DT120, an oral disintegrating tablet (ODT) formulation of LSD being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with an additional phase III study in post...

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Definium Therapeutics, Inc. (Nasdaq: DFTX) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying...

Leerink Partners Issues Positive Forecast for Definium Therapeutics (NASDAQ:DFTX) Stock Price

Leerink Partners increased their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the company an "outperform" rating in a report on Wednesday...

Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move

Definium Therapeutics stock rises after hours amid psychedelic sector rally following Trump's regulatory push.read more...

<ul class="summary-bullets"><li>Momentum across psychedelic stocks gained after Trump signed an exec order directing the FDA to accelerate review of psychedelic therapies and committed $50 million towards research.</li><li>The company said it holds standardized, stabilized GMP-compliant ibogaine doses in inventory in a market where access to clinical-grade material remains limited.</li><li>Through its investment in PsyLabs, Psyence has built a vertically integrated platform spanning sourcing in Africa through extraction, purification and pharma production.</li></ul>Shares of Psyence Biomedical (PBM) surged into the spotlight again on Monday after the company underscored its pharma-grade ibogaine inventory advantage just as a new White House order boosted momentum behind psychedelic medicine research.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has logged a three-day winning streak, gaining 182% over the same period.&nbsp;<h2 class="st-heading-2">PBM Targets Global Ibogaine Supply Gap</h2>Psyence Biomedical said on Monday that it currently holds standardized, stabilized and Good Manufacturing Practice (GMP)-compliant ibogaine doses in inventory in a market where access to pharma-grade material remains limited and fragmented.Through its investment in PsyLabs, the company has built an integrated platform spanning sourcing at origin in Africa through extraction, purification and pharmaceutical production.&nbsp;“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” CEO Jody Aufrichtig said. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”The company added that its vertically integrated platform can reduce delays tied in supply constraints that have historically slowed progress in ibogaine-based clinical research.<h2 class="st-heading-2">PBM Rides FDA Psychedelic Review Momentum</h2>The supply update comes shortly after U.S. President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite review of psychedelic medicines, including ibogaine, while committing $50 million in funding toward related clinical-research programs.At the Oval Office signing ceremony, Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence, particularly for veterans with serious mental-health conditions.&nbsp;Ibogaine, a compound derived from a Central and West African shrub, remains classified as a Schedule I substance in the U.S. but has attracted growing attention for its potential role in treating post-traumatic stress disorder.The policy move triggered a broad rally across psychedelic-therapy developers. Shares of Enveric Biosciences (ENVB) surged 101%, Compass Pathways (CMPS) jumped 42%, Atai Life Sciences (ATAI) gained 22%, and Definium Therapeutics (DFTX) rose 2% on Monday.<h2 class="st-heading-2">PBM Builds Ibogaine Supply From Africa&nbsp;</h2>Operating near ibogaine’s natural source in Central and West Africa, PsyLabs has secured direct access to raw material with in-region processing to support traceable, reliable, and ethically sourced supply.&nbsp;Earlier this year, Psyence said it produced high-purity ibogaine hydrochloride from ethically sourced iboga bark and exported a GMP-compliant psilocybin product, NPX-5, to Australia for a Phase IIb trial in adjustment disorder among patients receiving palliative cancer care.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM was ‘extremely bullish’ amid an eye-watering 82,550% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_36a8236907.webp" alt="pbm ss.png" width="967" height="133"><figcaption>TSLA sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LowDownDog12/message/650809854">said</a>, “Still holding my 5200 shares at 2.40. Bought believing this company could be the first to get ibogaine to market and still do.”<stembedurl>https://stocktwits.com/LowDownDog12/message/650809854</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/livetotradestox/message/650823742">noted</a> PBM's description of itself as the world’s only licensed pharma-grade ibogaine supplier at source level, and said: "Only sounds like a monopoly. At the very least a moat because of high barriers to entry for competitors."<stembedurl>https://stocktwits.com/livetotradestox/message/650823742</stembedurl>The stock has declined 48% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-founder-bull-case-anktiva-breast-cancer-signal/cZBIIqmRICd">IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push

PBM stock extended its rally to a three-day winning streak, gaining about 182% over the period as investors focused on supply benefits in the ibogaine ecosystem.

Equity

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric...

<ul class="summary-bullets"><li>Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.</li><li>Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.</li><li>Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.</li></ul> Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.<h2 class="st-heading-2">Wall Street Boost</h2>Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.<stembedurl>https://www.stocktwits.com/twiggs462/message/650773904</stembedurl>Another user cheered Atai’s great assets and voiced hopes for further rallies in future.<stembedurl>https://www.stocktwits.com/brunoq14/message/650772195</stembedurl><a href="https://stocktwits.com/symbol/ATAI">ATAI stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/agio-stock-slumps-whats-the-novo-connection/cZBd0tMRIzi">AGIO Stock Slumps 25% – What’s The Novo Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, spurring a rally among psychedelic drug developer stocks. 

Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week High  - Still a Buy?

Definium Therapeutics (NASDAQ:DFTX) Reaches New 1-Year High - Here's Why...

<ul class="summary-bullets"><li>Trump signed an executive order directing agencies to speed psychedelic research and approvals, alongside $50 million in federal funding for treatments such as ibogaine.</li><li>FDA Commissioner Marty Makary said aligned therapies could move through review timelines in weeks.</li><li>Koyfin consensus estimates suggest CMPS currently offers the larger implied upside, with 227% potential from recent levels, compared with about 62% for DFTX.</li></ul>A new White House push to fast-track psychedelic therapies has put Definium Therapeutics (DFTX) and Compass Pathways (CMPS) back in the spotlight, but analyst estimates suggest one may have significantly more upside from the policy shift.Both companies are advancing late-stage psychedelic therapies targeting psychiatric conditions, including depression, anxiety and post-traumatic stress disorder, placing them among the most directly exposed drug developers following the latest policy move.<a href="https://stocktwits.com/symbol/DFTX">DFTC stock</a> just posted its third straight week of gains, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS</a> ended last week 20% higher.&nbsp;<h2 class="st-heading-2">White House Pushes Speedy Psychedelic Research</h2>Over the weekend, U.S. President Donald Trump signed an executive order directing federal agencies to accelerate research, regulatory review and treatment access pathways tied to psychedelic medicines, including ibogaine, while committing $50 million in federal funding toward related clinical research.Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence and emphasized their potential role in addressing serious mental-health conditions affecting veterans and other patients.Health Secretary Robert F. Kennedy Jr. said the initiative aims to remove barriers limiting research into psychiatric therapies, while FDA Commissioner Marty Makary said at the Oval Office that certain psychedelic medicines aligned with national priorities could move through regulatory review timelines within weeks and not over a year.Although ibogaine was the only psychedelic referenced directly in the executive order, Definium’ LSD-based DT120 and Compass’ psilocybin therapy COMP360 are already advancing through late-stage clinical trials in the U.S. for major psychiatric indications.<h2 class="st-heading-2">CMPS Emerges As Higher-Upside Psychedelic Bet</h2>Consensus estimates compiled by Koyfin suggest that Compass Pathways currently offers the larger implied upside from recent levels.DFTX holds a 12-month average analyst price target of $36.67, implying a 62% upside from current levels, with 12 analysts rating the stock ‘Buy’ and four rating it ‘Strong Buy’.Meanwhile, CMPS carries a 12-month average analyst price target of $21.75, implying a 227% upside, with eight analysts rating the stock ‘Buy’, three rating it ‘Strong Buy’, and one rating it ‘Hold’, pointing to a substantially wider valuation runway from current levels.<h2 class="st-heading-2">Definium Positions DT120 For Regulatory Push</h2>Definium Therapeutics responded to the executive order and said: “A science-driven framework that supports rigorous evaluation, responsible access, and faster translation of innovation into care is essential, and the FDA’s evidence-based approval process provides the most effective path to safely delivering these therapies to patients.”The company is developing DT120, a pharmaceutical version of LSD, in late-stage clinical trials for generalized anxiety disorder (GAD) and major depressive disorder, with results from three large Phase 3 studies expected this year. The treatment has already received FDA Breakthrough Therapy Designation for anxiety.After initial reports of the executive order surfaced, Stifel initiated coverage with a ‘Buy’ rating and a $30 price target, citing DT120’s probability-of-success outlook in GAD. The firm also noted that Definium has the largest market cap among psychedelic-drug developers but said the sector remains broadly undervalued and is likely to produce multiple winners.<h2 class="st-heading-2">COMP360 Targets Depression And PTSD Markets</h2>Compass Pathways also welcomed the executive order, noting that about four million Americans living with treatment-resistant depression and 13 million with PTSD have seen limited innovation for decades. “With today’s Executive Order including the potential for accelerated regulatory and rescheduling processes, should COMP360 be approved, we will be ready to make this treatment available to patients,” the company said in a statement on Saturday.COMP360 has already produced two positive Phase 3 trials showing statistically significant improvement in depressive symptoms with effects appearing as early as one day after administration and durability lasting at least six months after one or two doses among responding patients.Compass is currently working with the FDA on a rolling submission strategy for treatment-resistant depression and is advancing additional development in post-traumatic stress disorder after receiving clearance to begin a Phase 2b/3 study.<h2 class="st-heading-2">How Do Retail Traders Feel About DFTX, CMPS?</h2>On Stocktwits, retail sentiment for both DFTX and CMPS was ‘extremely bullish’ amid ‘extremely high’ message volume.One user&nbsp;<a href="https://stocktwits.com/MichaelNaussCMT/message/650733439">expects</a> a “flurry of upgrades” for DFTX stock and said, “see you all on the moon”<stembedurl>https://stocktwits.com/MichaelNaussCMT/message/650733439</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/stevenryl86/message/650739263">noted</a> that CMPS is “the only one at late stage, and not to mentioned on the breakthrough designation. Multiple Phase 3&nbsp; and consistent success and closest to approval.”<stembedurl>https://stocktwits.com/stevenryl86/message/650739263</stembedurl>While DFTX stock has surged nearly 300% over the past year, CMPS has more than doubled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-pushes-back-ford-ceo-byd-best-ev-rival-limiting-factor-china/cZB5z15RIyW">Tesla CEO Elon Musk Pushes Back After Ford CEO Calls BYD Best EV Rival — Points To Key 'Limiting Factor' In China</a>

While DFTX stock has surged nearly 300% over the past year, CMPS has more than doubled over the same period. (Photo credit: Getty Images)

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Although ibogaine was the only therapy named in the order, Definium’s DT120 and Compass’ COMP360 treatments are already in late-stage U.S. trials for major psychiatric conditions.

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and...

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Current Price	$22.48
Prev Close	$23.26
Open	$23.26
Dividend Yield	0.00%
50-Day Moving Average	$19.19
Beta	1.75
Avg. Volume	1.79M
PE Ratio	-10.86

52-Week High	$26.25
52-Week Low	$6.03
Market Capitalization	$2.24B
EPS (Annual)	-$2.06
Price to Book	6.68
Revenue Per Employee	$0.00

DFTX
Definium Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DFTX News

DFTXDefinium Therapeutics Inc.